Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peg-IFN-α2b for HIV reservoir reduction
NCT02227277Phase 2Unknown
- Sponsor
- The Wistar Institute
- Start
- Feb 2015
- Primary completion
- Feb 2018
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in human immunodeficiency virus infection (HIV), sponsored by The Wistar Institute. Status: unknown.
02
Drugs
peginterferon alfa-2b
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT02227277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02227277.